Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Linear TMC-95-based proteasome inhibitors.

Nicolas Basse1, Sandrine Piguel, David Papapostolou

  • 1Laboratoire d'Enzymologie Moléculaire et Fonctionnelle, FRE 2852, CNRS, Université de Paris VI, Institut Jacques Monod, T43, 2 Place Jussieu, F 75251 Paris Cedex 05, France.

Journal of Medicinal Chemistry
|May 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biocompatible Nanoparticles Encapsulation of Fluorenyl-Porphyrins: Impact of Arm Structural Modifications on Two-Photon Phototherapeutic Performance.

Biomacromolecules·2026
Same author

Impact of Chelation on Reactivity and Cytotoxicity of Hemilabile Biphenyl Gold(III) N-Heterocyclic Carbene Complexes.

ChemMedChem·2025
Same author

Bioorthogonal Postlabeling Reveals Nuclear Localization of a Highly Cytotoxic Half-Sandwich Ir(III) Tetrazine Complex in Live Cells.

Chembiochem : a European journal of chemical biology·2025
Same author

FRET-based mesoporous organosilica nanoplatforms for <i>in vitro</i> and <i>in vivo</i> anticancer two-photon photodynamic therapy.

Journal of materials chemistry. B·2024
Same author

Protocol to generate, purify, and analyze antibody-oligonucleotide conjugates from off-the-shelf antibodies.

STAR protocols·2024
Same author

Allylboration of Ketones Catalyzed by BINOL Derivatives: Which Species Are Involved Depending on Substrate Reactivity?

The Journal of organic chemistry·2024
Same journal

Development of Indole-3-yl-methylene-thiobarbital Derivatives as Inhibitors of HDAC8 Enzyme Activity.

Journal of medicinal chemistry·2026
Same journal

Discovery of a Potent NAMPT-Targeting PROTAC for the Suppression of Triple-Negative Breast Cancer via Macrophage Reprogramming.

Journal of medicinal chemistry·2026
Same journal

3',4'-Isopropylidene-α-galactosylceramide Enables Multidose Th1 Adjuvanticity Despite Limited Serial Serum IFN-γ Responsiveness.

Journal of medicinal chemistry·2026
Same journal

A Bioorthogonally Cleavable <i>N</i>-Oxide Linker for Prodrug Design: Elucidating the Structure-Cyclization Kinetics Relationships for Controlled Drug Release.

Journal of medicinal chemistry·2026
Same journal

A Melatonin-Catechol Hybrid Molecule Prolongs Lifespan via Regulating ROS and Reprogramming Mitochondrial Metabolism.

Journal of medicinal chemistry·2026
Same journal

Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.

Journal of medicinal chemistry·2026
See all related articles

Researchers developed linear peptide analogues of TMC-95A, achieving submicromolar inhibition of proteasome catalytic sites. These compounds show potential as targeted cancer therapeutics due to their tunable selectivity and cytotoxicity against tumor cells.

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • The natural cyclopeptide TMC-95A is a potent proteasome inhibitor.
  • Cyclic peptides often present synthetic challenges and conformational constraints.
  • Understanding structure-activity relationships is key for developing novel therapeutics.

Purpose of the Study:

  • To design and evaluate linear analogues of TMC-95A.
  • To investigate the impact of structural modifications on proteasome inhibition.
  • To identify potent and selective proteasome inhibitors for cancer therapy.

Main Methods:

  • Synthesis of 45 linear peptide analogues based on the Y-N-W sequence.
  • Evaluation of inhibition efficiency and selectivity against proteasome catalytic sites.

Related Experiment Videos

  • Cytotoxicity assays on human tumor cell lines.

    • Main Results:

    • Linear analogues achieved submicromolar inhibition constants (Ki ≈ 300 nM).
    • Structural variations influenced inhibitor efficiency and selectivity for specific proteasome sites.
    • Compounds demonstrated tunable inhibition of one, two, or all three catalytic sites.
    • Potent inhibitors were identified against various human tumor cell lines.

    Conclusions:

    • Linear analogues of TMC-95A are synthetically accessible and stable.
    • These compounds offer a promising scaffold for developing targeted proteasome inhibitors.
    • Optimized linear peptides show potential as novel anti-cancer agents.